Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAT2A | P31153 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.38 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258828 | 0.88 | KDR (0.45) | KDRHSD17B1HSD17B2MAT2AFYN | |
| SCHEMBL5255461 | 0.83 | IKBKE (0.43) | MAT2AIKBKEFYNTGFBR1TGFBR2 | |
| SCHEMBL5258602 | 0.83 | IKBKE (0.48) | IKBKEFYNCYP1A2TGFBR1TGFBR2 | |
| SCHEMBL5258509 | 0.83 | IKBKE (0.42) | MAPK1IKBKEFYNTGFBR1TGFBR2 | |
| SCHEMBL5262878 | 0.80 | IKBKE (0.50) | IKBKETGFBR1TGFBR2KMT2A | |
| SCHEMBL5256792 | 0.80 | IKBKE (0.42) | MAOBIKBKEFYNTGFBR1TGFBR2 | |
| SCHEMBL5258063 | 0.80 | DYRK1B (0.44) | MAT2AFYNKMT2APDGFRBPDGFRA | |
| SCHEMBL13575397 | 0.79 | HSD17B1 (0.65) | KDREPHB4TEKHSD17B1HSD17B2 | |
| SCHEMBL5258957 | 0.78 | IKBKE (0.41) | IKBKEFYNKMT2A | |
| SCHEMBL5462134 | 0.76 | MAPK14 (0.50) | IKBKECHEK1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | claimed |
| CN-1264377-A | Substituted pyrazoles as P38 kinase inhabitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | claimed |
| EP-1000055-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1998052940-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| EP-1500657-B1 | Substituted pyrazoles as P38 kinase inhibitors | SEARLE LLC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-7153959-B2 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-7071198-B1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-6979686-B1 | Substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1500657-A1 | Substituted pyrazoles as P38 kinase inhibitors | G.D. Searle LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1144403-B1 | SUBSTITUTED PYRAZOLES AS P38 KINASE INHIBITORS | SEARLE LLC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | disclosed |
| CN-1342157-A | Substituted pyrazoles ASP38 kinase inhibitors | SEARLE & CO (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1144403-A1 | SUBSTITUED PYRAZOLES AS P38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2001-10-17 | — | — | EP | disclosed |
| CN-1273603-A | Attenuated respiratory syncytial virus | AMERICAN CYANAMID CO (US) | 2000-11-15 | — | — | CN | disclosed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-1000055-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998052940-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | MAPK1, IL1R1, TNF | KDR 3552/4885EPHB4 2372/4885TEK 2099/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | KDR 4855/4885EPHB4 4336/4885TEK 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.